Ultra-Pulsed Carbon Dioxide Laser for the Treatment of Melanocytic Nevi

Ali Mohamed G1* and Gamal Ahmed D2
Department of Dermatology, Benghazi University, Libya

*Corresponding author: Ali Mohamed Gargoom MD, Associate Professor of Dermatology, Dermatology Department, Faculty of Medicine, Benghazi University, Benghazi, Libya, Tel: 00218 92 511 3849; Email: gargoom@yahoo.com

Abstract
Congenital melanocytic nevi (CMN) even small-sized as well as acquired melanocytic nevi (AMN) are of common cosmetic concerns and getting rid of them remain challenging. The aim of this study is to evaluate the efficacy and safety of the ultra-pulsed CO2 laser for the treatment melanocytic nevi. Sixteen AMN and 7 CMN in 15 male and female Libyan patients were treated with multiple sessions ultra-pulsed CO2 laser at 1-month intervals. Clinical response at 6 months after final treatment was graded as poor (< 50%), moderate (50–75%), good (> 75%) and excellent where the skin of the lesion returned normal as the rest of the surrounding skin. All treated nevi showed good to excellent cosmetic outcomes after 2 or 4 treatment sessions. The post laser complications were minimal and transit except for one atrophic scar. No recurrence of pigmentation during the six months of follow-up period.

Keywords: UCO2; Laser; Melanocytic; Nevus; Acquired; Congenital

Introduction
Melanocytic nevi may present at birth in about 1% - 6% of newborn infants and referred as congenital melanocytic nevi (CMN) or may developed later on in life where known as acquired melanocytic nevi (AMN) [1,2]. Depending on the clinical examination solely, sometimes it is hardly possible to differentiate between congenital and acquired nevi and documentation since birth may be the only way to prove the congenital origin [3].

Congenital melanocytic nevi classified according to their surface areas into; small CMN with a diameter < 1.5 cm, medium-sized CMN measure between 1.5 and 19.5 cm and large CMN with diameters > 19.5 cm [2,4]. Acquired melanocytic nevi may be junctional, compound or dermal [5].

Different modality of treatment were tried to treat melanocytic nevi including; surgical excision, cryotherapy, dermabrasion, curettage and chemical peeling. Although some of this modality of treatment is effective in removing the nevi but the risk of dyschromia and scar formation limit their uses. Nevertheless, nevi in esthetically sensitive or surgically challenging areas and large nevi is another important obstacle. In these conditions laser treatment of melanocytic nevi is the appropriate alternative choice [5,6]. Both pigment-specific alexandrite (Al, 755 nm), neodymium: yttrium-aluminum-garnet (Nd:YAG, 1064 nm) and frequency-doubled Nd:YAG laser (fd Nd:YAG, 532 nm) and ablating lasers such as carbon dioxide (CO2) and erbium: yttrium-aluminum-garnet (Er:YAG) and in combination with each other, have been found to be effective in the treatment of
melanocytic nevi but with variable outcome and sequels [5-8].

Histological examination after various laser procedures reveals persistence of nevomelanocytic cells in the papillary dermis which increase the possibility of recurrence. For this reason, long-pulsed pigment-specific laser and ablating laser are more efficient [5].

Carbon dioxide laser in continuous mode is among the effective ablative laser systems in the treatment of melanocytic nevi. However, due to its uncontrollable penetration depth associated with a great possibility of textural changes and post-laser pigmentary alteration especially in patients with dark skin. The emergence of the superpulsed CO₂ laser and more recently the ultrapulsed CO₂ (UCO₂) laser which delivers high energy beam in very short impulses minimizes the risks of scarring [8,9]. The present work was designed to evaluate the efficiency and safety of UCO₂ laser ablation in the treatment of melanocytic nevi in a group of patients with skin type III and IV.

Materials and Methods

Between January 2016 and October 2017, fifteen male and female Libyan patients aged between 15 years to 35 years (mean age 19.3 years) with a total of 23 clinically benign-appearing melanocytic nevi were enrolled in the present study. Sixteen out of the 23 studied nevi were AMN and seven were CMN. Melanocytic nevi with a diameter of 3 cm or larger or with variable color, irregular border, and asymmetry were excluded. Melanocytic nevi with sudden increase in size or textural changes were also excluded. All included patients had Fitzpatrick’s skin types IV and V. Pregnant or lactating female or patients with keloid tendency or family history of melanoma were excluded.

Laser procedure, the potential complications and the expected outcomes were explained to every patient prior to laser session. An informed consent was obtained from each patient. The lesions were cleaned with disinfecting solution then infiltrated with 2% lignocaine via insulin syringe attached to 29-G needle. Lesions were treated with UCO₂ laser (Fraxis from ilooda; 10,600 nm; 100-200 Hz; 200-400 μs) with fixed spot-size handpiece (spot diameter 100 mm). The photoablated tissue was gently removed with a cotton swap soaked in normal saline and the end point was the appearance of fine punctuate bleeding (level of papillary dermis). Laser photoablation and gentle removal of photoablated tissue was repeated for 2-4 passes until the appearance of underlying pink tissue which was considered as the endpoint of laser photoablation. Post-operatively, patients were instructed to apply fusidic acid cream till crust formation and to keep the area clean and dry for the same duration. Photographic documentation of the lesion before laser treatment and immediately afterward and then reviewed at day 2, day 7, 1 month, 2 months, 4 months and finally at 9 months. Before and after photo were taken with Canon XUS 220 HS camera.

The clinical response is graded by the treating physicians into four categories: excellent clearance (the skin of the lesion returned normal as the rest of the surrounding skin and does not need further treatment); good clearance (>75% cleared); moderate clearance (>50-75% cleared); and poor clearance (<50% cleared).

Patients satisfaction questionnaire using a 4-point grading scale as follows: very satisfied, satisfied, somewhat satisfied and dissatisfied was completed by every patient at the end of follow up period. Any possible complications and side effects (erythema, texture changes, scarring, postinflammatory pigmentations) were recorded during post-operative follow-ups.

Results

Fifteen patients (11 female and 4 male) with 23 clinically benign-appearing melanocytic nevi completed the study. The mean age of the patients was 19.3 years (range 15-35). All included melanocytic nevi were involving the face. Among the sixteen AMN, 9 (39%) were flat or just palpable pigmented lesion and categorized based on naked eye examination as junctional AMN while 7 (30%) were dome-shape pigmented lesion and considered as compound AMN. While among the seven CMN, 6 (26%) were smaller than 1.5 cm and categorized as small CMN and one (4%) measured 2.3 cm which was considered as medium sized CMN (Figure 1).

Figure 1: Clinical Types of the Studied Nevi
Seventy four treatment sessions were done using UCO2 laser and the number of treatments ranged from two to four sessions one month apart for every nevi (mean of 3.4 sessions). Two to four passes with UCO2 laser was undertaken in every laser session. Fifty-two percent (52%) of the included series showed good clearance of melanocytic nevi (clearance >75%) (Figure 2A and 2B) and 48% showed excellent results (Figure 3A – 4B) after two or four UCO2 laser sessions. 

<table>
<thead>
<tr>
<th>Type of nevi</th>
<th>Number</th>
<th>Poor, No. (%)</th>
<th>Moderate, No. (%)</th>
<th>Good, No. (%)</th>
<th>Excellent, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Junctional</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>3 (33)</td>
<td>6 (67)</td>
</tr>
<tr>
<td>Compound</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>4 (57)</td>
<td>3 (43)</td>
</tr>
<tr>
<td>Small CMN</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>4 (67)</td>
<td>2 (33)</td>
</tr>
<tr>
<td>Medium CMN</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>23</td>
<td>0</td>
<td>0</td>
<td>12 (52)</td>
<td>11 (48)</td>
</tr>
</tbody>
</table>

Table 1: Treatment Responses of the 23 Benign-appearing Melanocytic Nevi after Treatment with Ultrapulsed CO2 Laser according to the Type of Nevus.

Figure 2: Fifteen years old female with medium-sized CMN just below the right nostril before (A) and after the fourth session of UCO2 laser treatment (B) showing good clearance (> 75% clearance).

Figure 3: Twenty-two years old male patient with small CMN on forehead before (A) treatment and 6 months after second treatment session (B).
Figure 4: Forty-five years old male with compound AMN on nose for more than ten years duration before (A) and 6 months after two laser sessions (B).

Figure 5: Overall Patients Satisfaction at the End of the Study. Figure 5, summarizes the assessment of patient satisfaction with the treatment results at the end of follow up period. Only one patient with small-sized CMN in this study showed mild textural changes during the post-operative follow period (Figure 6A and 6B).

Figure 6: 16-years old Libyan male patient with small-sized CMN above the left eyebrow before (A) treatment and 2-months after the second session of UCO₂ laser treatment (B).
Discussion

Melanocytic nevi can be simply classified into congenital and acquired based on their first appearance since birth or thereafter. However, some CMN may not be obvious at birth but they gradually develop pigment over time and become apparent [2,4]. Generally, CMN are found to be much larger in diameter than acquired nevi. Majority of CMN are 5 mm or more in diameter at birth while most of AMN never grow to more than 5 mm [4]. AMN is benign proliferations of melanocytic naevus cells which occur initially within the epidermis at the dermo-epidermal junction hence called junctional melanocytic nevi. Further cellular proliferation results in the migration of nevus cells and their localization within the papillary dermis forming what is known as dermal melanocytic nevi. When the melanocytic naevus cells present in the dermo-epidermal junction and in the dermis, they are termed compound melanocytic nevi [5].

Various laser modality were used to treat melanocytic nevi including: pigment-selective (AL, Nd:YAG and fs Nd: YAG), ablative lasers (Er: YAG and CO₂) and combination of pigment-selective and ablating lasers; all have been found to be effective in the treatment of MN with variable outcomes and sequels. There are two types of pigment-selective laser the long-pulsed (msec) and short-pulsed (Q-switched nsec lasers) devices [5]. Most authors have agreed that the use of pigment-selective lasers either in the short-pulsed mode (Q-switched nsec) or in the long-pulsed mode (msec) is effective in superficial nevi i.e. junctional nevi but with limited results in deeper lesions (compound and dermal nevus). Moreover, associated with high rate of recurrence [5,10]. This is because pigment-specific lasers treat the superficial nevomelanocytes located in papillary dermis, but is unlikely to affect the deeply-seated nevomelanocytes. Which has been demonstrated histologically as persistent nevomelanocytic nests in the mid papillary and deeper dermis at depths of 0.16–0.44 mm following pigment-specific lasers sessions [7].

The principle of combination of pigment-selective and ablating lasers is to facilitate the delivery of laser beam of the pigment-selective lasers to reach to the deeply-seated nevomelanocytes after ablation of the superficial cells by the ablating lasers. This is in contrary to August et al. who concluded that pretreatment of CMN with CO₂ laser appears no more effective than pigment-specific laser alone and may increase the incidence of adverse effects [7,8].

Ablating lasers (Er: YAG and CO₂) work by destroying the target cells directly and the depth can be achieved by adjusting the dose. Er: YAG laser ablates nearly 5–50 μm per pass while the UCO₂ laser has a higher ablation depth of 20–60 μm per pass and causes higher thermal coagulation which explain its complete destruction of nevus cells that minimize the risk of recurrence [5].

Carbon dioxide laser considered as the gold standard in ablative lasers with its wavelength (10.600nm) which is selectively absorbed by water. Since approximately 77% of skin consists of water, this absorption was the optimal condition for the ablation effect. The major drawback of CO₂ laser in the continuous mode is considerable possibility of texture changes because of its uncontrollable penetration depth. The newer ultrapulsed CO₂ laser mode that emits a substantially very high energy in extremely short pulses that lies outside the thermal relaxation time of skin (<1 msec) hence minimizing the collateral destruction [5]. According to many authors if the dose depth correlation is properly ensured the UCO₂ laser is a fantastic tool.

The overall results of our study pointed out that all included patients showed good to excellent results (Table 1). This is come in accordance with Eggen, et al. who recently systematically reviewed 24 studies with 20 different types of laser treatments in 434 patients and concluded that good to excellent result can be achieved in all laser categories [8]. The best result in our series where accomplished from the AMN patients where 52% of patients showed good clearance (>75% cleared) and 48% showed excellent results i.e. the skin returned to almost normal appearance. This promising outcome from our series is attributed obviously to the included AMN patients who comprise only junctional and compound nevi. The response of junctional and compound AMN is much better than dermal one, this is in consistence with many other studies [5,7,8].

Regarding the studied six small size CMN, (67%) showed good response and (23%) showed excellent outcomes. The only one medium size CMN which measured 3.5cm ended with complete clearance of the pigmentation but with mild textural changes though patient’s satisfaction is very good. The small number of included patients in our study is the major limitation. Furthermore, the lack of post-treatment histopathological report and the relatively short follow up period (6 months) represent another important drawback.
Malignant changes in nevi as a consequence to laser therapy remain of much worry and obstacle for practitioner in this field of dermatology but such burden have not been proved clinically [7]. Moreover recently, according to Eggen, et al. treatment of melanocytic nevi with laser carry low risk of malignant transformation in contrary to the old assumption [8]. According to the author’s opinion, this recent assumption will open the doors and will account for more liberal use of laser in this critical dermatological issue.

Conclusion

UCO2 laser is a marvelous device especially by expertise practitioner and represent a convenient substitute to the conventional methods in the treatment of melanocytic nevus. It is a quick out-patient procedure, well tolerable by patient, need minimal postoperative care, associated with low risk of visible scarring and low recurrence rate. Moreover, a positive esthetic outcome. Therefore; we recommend the UCO2 laser for the treatment of melanocytic nevi but further studies with larger number of patients and longer duration of follow up is needed to prove the efficacy and safety of this procedure.

References